MARKET

EIKN

EIKN

Eikon Therapeutics
NASDAQ
10.02
+0.34
+3.46%
Opening 10:16 05/04 EDT
OPEN
9.75
PREV CLOSE
9.68
HIGH
10.07
LOW
9.70
VOLUME
55.86K
TURNOVER
--
52 WEEK HIGH
17.40
52 WEEK LOW
7.90
MARKET CAP
540.65M
P/E (TTM)
-1.6204
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at EIKN last week (0427-0501)?
Weekly Report · 7h ago
Domino's Posts Downbeat Q1 Results, Joins Real Brokerage And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Benzinga · 04/27 12:02
Weekly Report: what happened at EIKN last week (0420-0424)?
Weekly Report · 04/27 10:47
Weekly Report: what happened at EIKN last week (0413-0417)?
Weekly Report · 04/20 10:41
Weekly Report: what happened at EIKN last week (0406-0410)?
Weekly Report · 04/13 10:47
Largest IPOs of the last 90 days register mixed debut
Seeking Alpha · 04/06 15:39
Weekly Report: what happened at EIKN last week (0330-0403)?
Weekly Report · 04/06 10:47
Wedbush Reiterates Underperform on Eikon Therapeutics, Maintains $7 Price Target
Benzinga · 03/31 14:18
More
About EIKN
Eikon Therapeutics, Inc. is a late-stage clinical biopharmaceutical company, which is focused on advancing a pipeline of potential therapies for patients with unmet medical needs. The Company has clinical programs at various stages of development, and active discovery efforts in oncology and neurological disease. Its pipeline includes EIK1001 TLR7/8 Melanoma, EIK1001 TLR7/8 NSCLC, EIK1003 PARP1, EIK1004 PARP1, EIK1005 WRN Phase 1, EIK1006, and AR-V7. EIK1001 is a systemically administered dual-agonist of toll-like receptors 7 and 8 that has demonstrated single-agent activity, as well as activity in combination with anti-PD-(L)1 agents, across multiple solid tumor types in Phase 1 trials. EIK1003 targets PARP1, a central component of DNA repair machinery in normal cells. EIK1003 is being evaluated in a Phase 1/2 study of patients with breast, ovarian, or prostate malignancies that have known or suspected deleterious mutations of select homologous recombination repair (HRR) genes.

Webull offers Eikon Therapeutics,Inc stock information, including NASDAQ: EIKN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EIKN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EIKN stock methods without spending real money on the virtual paper trading platform.